Relationship between grades of macular perfusion and foveal thickness in branch retinal vein occlusion

Clinical Ophthalmology

Volumn 7, Issue 1, 2012, Pages 39-45

  Sakimoto, Susumu ^a   Kamei, Motohiro ^a   Suzuki, Mihoko ^a   Yano, Shinsaku ^a   Matsumura, Nagakazu ^a   Sakaguchi, Hirokazu ^a   Gomi, Fumi ^a   Nishida, Kohji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Branch retinal vein occlusion; Foveal thickness; Macular edema; Macular perfusion

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOVEAL THICKNESS; HUMAN; MACULAR PERFUSION; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATIENT ASSESSMENT; RETINA CAPILLARY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; VISUAL SYSTEM PARAMETERS;

EID: 84872706825     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S37185     Document Type: Article

References (25)

1. Branch Vein Occlusion Study Group. Argon laser scatter photocoagula-tion for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Arch Ophthalmol. 1986;104(1):34-41.
2. Shilling JS, Jones CA. Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol. 1984;68(3):196-198.
3. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094-1101.
4. Branch Vein Occlusion Study Group. Argon laser photocoagula-tion for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271-282.
5. Michels RG, Gass JD. The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol. 1974;78(2): 166-177.
6. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol. 1974; 78(2):178-192.
7. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevaci-zumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27(4):419-425.
8. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92(4):518-522.
9. Cekiç O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2005;25(7):851-855.
10. Chen SD, Lochhead J, Patel CK, Frith P. Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol. 2004;88(1):154-155.
11. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascu-lar endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006;244(3):309-315.
12. Prasad PS, Oliver SC, Coffee RE, et al. Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. Ophthalmology. 2010;117(4):780-784.
13. Shroff D, Mehta DK, Arora R, et al. Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography study. Int Ophthalmol. 2008;28(4):261-268.
14. Finkelstein D. Ischemic macular edema: recognition and favor-able natural history in branch vein occlusion. Arch Ophthalmol. 1992;110(10):1427-1434.
15. Marcussen N, Olsen TS, Benediktsson H, Racusen L, Solez K. Reproducibility of the Banff classification of renal allograft pathology. Inter-and intraobserver variation. Transplantation. 1995;60(10): 1083-1089.
16. Archer DB, Deutman A, Ernest JT, Krill AE. Arteriovenous commu-nications of the retina. Am J Ophthalmol. 1973;75(2):224-241.
17. Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology. 1999;106(11): 2054-2062.
18. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982;100(7):1132-1140.
19. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator. Mol Ther. 2008;16(4):791-799.
20. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604-4613.
21. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843-845.
22. Scott IU, Van Veldhuisen PC, Oden NL, et al. SCORE Study report 1: baseline associations between central retinal thickness and visual acu-ity in patients with retinal vein occlusion. Ophthalmology. 2009; 116(3):504-512.
23. Ota M, Tsujikawa A, Murakami T, et al. Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2008;145(2):273-280.
24. Avunduk AM, Cetinkaya K, Kapicioǧlu Z, Kaya C. The effect of posterior vitreous detachment on the prognosis of branch retinal vein occlusion. Acta Ophthalmol Scand. 1997;75(4):441-442.
25. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33(2): 111-131.